The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
XENOGENEIC TRANSPLANTATION
Abstract
▪ Abstract This review summarizes the clinical history and rationale for xenotransplantation; recent progress in understanding the physiologic, immunologic, and infectious obstacles to the procedure's success; and some of the strategies being pursued to overcome these obstacles. The problems of xenotransplantation are complex, and a combination of approaches is required. The earliest and most striking immunologic obstacle, that of hyperacute rejection, appears to be the closest to being solved. This phenomenon depends on the binding of natural antibody to the vascular endothelium, fixation of complement by that antibody, and finally, activation of the endothelium and initiation of coagulation. Therefore, these three pathways have been targeted as sites for intervention in the process. The mechanisms responsible for the next immunologic barrier, that of delayed xenograft/acute vascular rejection, remain to be fully elucidated. They probably also involve multiple pathways, including antibody and/or immune cell binding and endothelial cell activation. The final immunologic barrier, that of the cellular immune response, involves mechanisms that are similar to those involved in allograft rejection. However, the strength of the cellular immune response to xenografts is so great that it is unlikely to be controlled by the types of nonspecific immunosuppression used routinely to prevent allograft rejection. For this reason, it may be essential to induce specific immunologic unresponsiveness to at least some of the most antigenic xenogeneic molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity
Bezouška, K., Yuen, C.-T., O'Brien, J., Childs, R. A., Chai, W., Lawson, A. M., Drbal, K., Fišerová, A., Posíšil, M., & Feizi, T. (1994) · Nature · doi:10.1038/372150a0 · Cited by 250
RetractedLong-Term Survival of Xenogeneic Pancreatic Islet Grafts Induced by CTLA4lg
Lenschow, D. J., Zeng, Y., Thistlethwaite, J. R., Montag, A., Brady, W., Gibson, M. G., Linsley, P. S., & Bluestone, J. A. (1992) · Science · doi:10.1126/science.1323143 · Cited by 1,121
Infection of human cells by an endogenous retrovirus of pigs
Patience, C., Takeuchi, Y., & Weiss, R. A. (1997) · Nature Medicine · doi:10.1038/nm0397-282 · Cited by 953
Ballas, Z. K., Rasmussen, W. L., & Krieg, A. M. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.5.1840 · Cited by 754
Ildstad, S. T., & Sachs, D. H. (1984) · Nature · doi:10.1038/307168a0 · Cited by 750
Self-citationCD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2.
Sayegh, M. H., Akalin, E., Hancock, W. W., Russell, M. E., Carpenter, C. B., Linsley, P. S., & Turka, L. A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.5.1869 · Cited by 511
Baboon-to-human liver transplantation
Starzl, T. E., Fung, J., Tzakis, A., Todo, S., Demetris, A. J., Marino, I. R., Doyle, H., Zeevi, A., Warty, V, Kusne, S., et al. (1993) · The Lancet · doi:10.1016/0140-6736(93)92553-6 · Cited by 471
Deacon, T., Schumacher, J., Dinsmore, J., Thomas, C., Palmer, P., Kott, S., Edge, A., Penney, D., Kassissieh, S., Dempsey, P., et al. (1997) · Nature Medicine · doi:10.1038/nm0397-350 · Cited by 463
Baboon-to-Human Cardiac Xenotransplantation in a Neonate
Bailey, L. L. (1985) · JAMA · doi:10.1001/jama.1985.03360230053022 · Cited by 458
Sun, Y., Ma, X., Zhou, D., Vacek, I., & Sun, A. M. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118929 · Cited by 453
Cited by
Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778
Antibody-mediated organ-allograft rejection
Colvin, R. B., & Smith, R. N. (2005) · Nature Reviews Immunology · doi:10.1038/nri1702 · Cited by 492
Macher, B. A., & Galili, U. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2007.11.003 · Cited by 404
XENOGENEIC EXTRACELLULAR MATRIX GRAFTS ELICIT A TH2-RESTRICTED IMMUNE RESPONSE1
Allman, A. J., McPherson, T. B., Badylak, S. F., Merrill, L. C., Kallakury, B., Sheehan, C., Raeder, R. H., & Metzger, D. W. (2001) · Transplantation · doi:10.1097/00007890-200106150-00024 · Cited by 388
Neural transplantation for the treatment of Parkinson's disease
Björklund, A., Dunnett, S. B., Brundin, P., Stoessl, A. J., Freed, C. R., Breeze, R. E., Levivier, M., Peschanski, M., Studer, L., & Barker, R. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00442-3 · Cited by 356
Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts
Swijnenburg, R.-J., Schrepfer, S., Govaert, J. A., Cao, F., Ransohoff, K., Sheikh, A. Y., Haddad, M., Connolly, A. J., Davis, M. M., Robbins, R. C., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805802105 · Cited by 297
Human and porcine early kidney precursors as a new source for transplantation
Dekel, B., Burakova, T., Arditti, F. D., Reich-Zeliger, S., Milstein, O., Aviel-Ronen, S., Rechavi, G., Friedman, N., Kaminski, N., Passwell, J. H., et al. (2003) · Nature Medicine · doi:10.1038/nm812 · Cited by 291
Factors in Xenograft Rejection
ROBSON, S. C., AM ESCH, J. S., & BACH, F. H. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb08509.x · Cited by 71
Eisenson, D. L., Hisadome, Y., & Yamada, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.899657 · Cited by 55
Metadata
- Authors
- Auchincloss, H., & Sachs, D. H.
- Venue
- Annual Review of Immunology
- Publisher
- Annual Reviews
- Published
- 1998-04
- Volume
- 16
- Issue
- 1
- Pages
- 433-470
- ISSN
- 0732-0582 (ISSN-L)
- 1545-3278
- OpenAlex
- W4251829470
- Cited by
- 372
- References
- 95
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.